Presentazione di PowerPoint

1
Montalescot G, et al. Lancet 2009373723-31
2
Trial profile
Montalescot G, et al. Lancet 2009373723-31
3
Baseline characteristics of STEMI cohort, by
drug allocation and type of PCI
Montalescot G, et al. Lancet 2009373723-31
4
Major efficacy and safety endpoints at 30 days
Montalescot G, et al. Lancet 2009373723-31
5
Major efficacy and safety endpoints at 15 months
Montalescot G, et al. Lancet 2009373723-31
6
Kaplan-Meier curves for selected endpoints
Montalescot G, et al. Lancet 2009373723-31